Literature DB >> 2577983

Tumor-localizing properties of porphyrins. In vitro studies using the porphyrin precursor, aminolevulinic acid, in free and liposome encapsulated forms.

H Fukuda1, S Paredes, A M Batlle.   

Abstract

Tumor, liver, skin and brain explants from tumor-bearing mice were cultured for 6, 12 and 22 hours in the presence of 0.06, 0.1 and 0.2 mM aminolevulinic acid (ALA). It was found that in all organs, synthesis of porphyrins increased with time and ALA concentration. The synthesising activity of tumor was high, of the same order as that of liver, and nearly twice that of skin and brain. The tissue/tumor porphyrin concentration ratios were lower than 0.5 at longer times and higher ALA concentration. In the case of skin/tumor the lowest ratio was about 0.2 and was obtained with 0.2 mM ALA. Chromatographic analysis of individual porphyrins showed that the whole heme pathway was functional in all organs studied, including tumor. Porphyrin synthesis by different organs from tumor bearing and normal mice was comparatively investigated using free and liposome encapsulated ALA. After 22 hours of incubation with 0.4 mM ALA, porphyrin formation was greater when encapsulated ALA was used. Accumulation of porphyrins in tumor was very high. The levels of activity were the same in each pair of organs in either the tumor-bearing mice or the control. These results indicate that free or encapsulated ALA may be used for the detection of tumors and in photodynamic therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577983

Source DB:  PubMed          Journal:  Drug Des Deliv        ISSN: 0884-2884


  10 in total

Review 1.  Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives.

Authors:  F S De Rosa; M V Bentley
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Heptamethine cyanine based (64)Cu-PET probe PC-1001 for cancer imaging: synthesis and in vivo evaluation.

Authors:  Li Xiao; Yi Zhang; Wei Yue; Xiuzhen Xie; Ji-Ping Wang; Mahendra D Chordia; Leland W K Chung; Dongfeng Pan
Journal:  Nucl Med Biol       Date:  2013-02-01       Impact factor: 2.408

Review 3.  Protoporphyrin IX: the Good, the Bad, and the Ugly.

Authors:  Madhav Sachar; Karl E Anderson; Xiaochao Ma
Journal:  J Pharmacol Exp Ther       Date:  2015-11-20       Impact factor: 4.030

4.  Stimulation of tetrapyrrole synthesis in mammalian epithelial cells in culture by exposure to aminolaevulinic acid.

Authors:  R Washbrook; H Fukuda; A Battle; P Riley
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Comparative effect of ALA derivatives on protoporphyrin IX production in human and rat skin organ cultures.

Authors:  A Casas; A M Batlle; A R Butler; D Robertson; E H Brown; A MacRobert; P A Riley
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

6.  ALA and ALA hexyl ester in free and liposomal formulations for the photosensitisation of tumour organ cultures.

Authors:  A Casas; C Perotti; M Saccoliti; P Sacca; H Fukuda; A M del C Batlle
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

7.  Tissue distribution and kinetics of endogenous porphyrins synthesized after topical application of ALA in different vehicles.

Authors:  A Casas; H Fukuda; A M Batlle
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

8.  Kinetics and localisation of PpIX fluorescence after topical and systemic ALA application, observed in skin and skin tumours of UVB-treated mice.

Authors:  N van der Veen; H S de Bruijn; R J Berg; W M Star
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

9.  ALA and ALA hexyl ester induction of porphyrins after their systemic administration to tumour bearing mice.

Authors:  C Perotti; A Casas; H Fukuda; P Sacca; A Batlle
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

10.  Porphyrin synthesis from ALA derivatives for photodynamic therapy. In vitro and in vivo studies.

Authors:  C Perotti; H Fukuda; G DiVenosa; A J MacRobert; A Batlle; A Casas
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.